Title : Catalpol synergistically potentiates the anti-tumour effects of regorafenib against hepatocellular carcinoma via dual inhibition of PI3K/Akt/mTOR/NF-κB and VEGF/VEGFR2 signaling pathways.

Pub. Date : 2021 Nov

PMID : 34596810






3 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Catalpol synergistically potentiates the anti-tumour effects of regorafenib against hepatocellular carcinoma via dual inhibition of PI3K/Akt/mTOR/NF-kappaB and VEGF/VEGFR2 signaling pathways. regorafenib mechanistic target of rapamycin kinase Homo sapiens
2 In addition, results revealed that our novel combination of catalpol and regorafenib showed potent synergistic anti-tumour effect via suppressing both of PI3K/p-Akt/mTOR/NF-kappaB and VEGF/VEGFR2 signaling pathways and their downstreams. regorafenib mechanistic target of rapamycin kinase Homo sapiens
3 CONCLUSION: Catalpol and/or regorafenib markedly suppressed PI3K/p-Akt/mTOR/NF-kappaB and VEGF/VEGFR2 signaling pathways and consequently showed potent anti-tumour effects against HCC. regorafenib mechanistic target of rapamycin kinase Homo sapiens